Search research articles
Contact Us
Filters
Showing results (41-50 of 48) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 48 results.
European Journal of Cancer (Oxford, England : 1990)
|
April 11, 2013
Modern multidisciplinary treatment of rectal cancer based on staging with magnetic resonance imaging leads to excellent local control, but distant control remains a challenge
S M E Engelen, M Maas, M J Lahaye, et al.
Nederlands Tijdschrift Voor Geneeskunde
|
April 3, 2008
[Angiogenesis inhibitors for the systemic treatment of metastatic renal cell carcinoma: sunitinib, sorafenib, bevacizumab and temsirolimus]
P H M de Mulder, J B A G Haanen, S Sleijfer, et al.
Biochimica Et Biophysica Acta. Molecular Basis of Disease
|
December 28, 2016
Severe fluoropyrimidine toxicity due to novel and rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing
André B P van Kuilenburg, Judith Meijer, Dirk Maurer, et al.
The Lancet. Oncology
|
July 19, 2014
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial
Walter Taal, Hendrika M Oosterkamp, Annemiek M E Walenkamp, et al.
Lancet (London, England)
|
April 12, 2015
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group
Lieke H J Simkens, Harm van Tinteren, Anne May, et al.
Genome Medicine
|
August 15, 2024
Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYD
Jonathan E Knikman, Qinglian Zhai, Carin A T C Lunenburg, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 14, 2018
A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy
Linda M Henricks, Carin A T C Lunenburg, Femke M de Man, et al.
The Lancet. Oncology
|
October 24, 2018
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis
Linda M Henricks, Carin A T C Lunenburg, Femke M de Man, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 48) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 48 results.
European Journal of Cancer (Oxford, England : 1990)
|
April 11, 2013
Modern multidisciplinary treatment of rectal cancer based on staging with magnetic resonance imaging leads to excellent local control, but distant control remains a challenge
S M E Engelen, M Maas, M J Lahaye, et al.
Nederlands Tijdschrift Voor Geneeskunde
|
April 3, 2008
[Angiogenesis inhibitors for the systemic treatment of metastatic renal cell carcinoma: sunitinib, sorafenib, bevacizumab and temsirolimus]
P H M de Mulder, J B A G Haanen, S Sleijfer, et al.
Biochimica Et Biophysica Acta. Molecular Basis of Disease
|
December 28, 2016
Severe fluoropyrimidine toxicity due to novel and rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing
André B P van Kuilenburg, Judith Meijer, Dirk Maurer, et al.
The Lancet. Oncology
|
July 19, 2014
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial
Walter Taal, Hendrika M Oosterkamp, Annemiek M E Walenkamp, et al.
Lancet (London, England)
|
April 12, 2015
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group
Lieke H J Simkens, Harm van Tinteren, Anne May, et al.
Genome Medicine
|
August 15, 2024
Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYD
Jonathan E Knikman, Qinglian Zhai, Carin A T C Lunenburg, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 14, 2018
A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy
Linda M Henricks, Carin A T C Lunenburg, Femke M de Man, et al.
The Lancet. Oncology
|
October 24, 2018
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis
Linda M Henricks, Carin A T C Lunenburg, Femke M de Man, et al.
Page
of 5